Sartorius completed its €33m ($45m) acquisition of Tap Biosystems earlier this week, in a move designed to bolster its offering in laboratory and small-scale commercial biomanufacturing systems.
Christel Fenge, manager of fermentation tech at Sartorius Stedim Biotech, told BioPharma-Reporter.com Ambr is “a perfect fit with our existing single-use benchtop and large scale single-use bioreactors.
“We are now able to offer a seamless path to scaling up processes based on proven and well understood stirred tank technology starting in the Ambr 15 and 250 products to clinical and commercial production using our Biostat STR.”
She also said Sartorius will continue to support Ambr customers, which will be good news for existing customer Cobra Biologics which told us last month that it would prefer to keep working with the same Tap support staff after the takeover was completed.
Fenge said: “We will continue to very actively support our Ambr customers and expand this platform further especially focusing on process analytical technologies and chemometrics tools and linking it to our downstream technologies such as membrane adsorption chromatography.”
Sartorius also expects Tap to bolster its biomanufacturing tech offering in other areas according to Fenge who said: “TAP fits perfectly to our bioreactor/fermenter business and our activities in the area of process analytical technologies.”
She explained that adding highly automated, multiparallel small scale bioreactor systems to Sartorius’ existing offering will help the firm “address the needs of our biopharma customers to increase throughput and efficiency especially in the process development area even further.
Tap also adds complementary competencies to Sartorius business in the area of robotics and liquid handling automation.